fda.gov
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
The FDA expanded Casgevy’s approval to patients aged 2 years and older with sickle cell disease involving recurrent vaso-occlusive crises or transfusion-dependent β thalassemia.
